Insights That Move the GPCR Field Forward

Read the latest analyses, interviews, and discoveries shaping the GPCR ecosystem — from research breakthroughs to biotech strategy.

Blog: Blog2

Search

Trevena Reports Second Quarter 2022 Results and Provides Business Update

August 2022 "CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the...

Aug 1, 20221 min read

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group...

Apr 1, 20221 min read

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with...

Apr 1, 20221 min read

February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical...

Feb 1, 20221 min read

December 2021 "3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in...

Dec 1, 20211 min read

November 2021 "November 11, 2021 7:00am EST Patricia Drake appointed new Chief Commercial Officer CHESTERBROOK, Pa., Nov. 11, 2021 --...

Nov 1, 20211 min read